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STUDY PROTOCOL Open Access
Keratinocyte growth factor in acute lung injury to
reduce pulmonary dysfunction – a randomised
placebo-controlled trial (KARE): study protocol
Laurence JM Cross1,2, Cecilia M O’Kane1, Cliona McDowell3, Jospeh J Elborn1, Michael A Matthay4,5
and Daniel F McAuley1,2*
Abstract
Background: Acute lung injury is a common, devastating clinical syndrome associated with substantial mortality
and morbidity with currently no proven therapeutic interventional strategy to improve patient outcomes. The
objectives of this study are to test the potential therapeutic effects of keratinocyte growth factor for patients with
acute lung injury on oxygenation and biological indicators of acute inflammation, lung epithelial and endothelial
function, protease:antiprotease balance, and lung extracellular matrix degradation and turnover.
Methods/design: This will be a prospective, randomised, double-blind, allocation-concealed, placebo-controlled,
phase 2, multicentre trial. Randomisation will be stratified by presence of severe sepsis requiring vasopressors.
Patients in an ICU fulfilling the American–European Consensus Conference Definition of acute lung injury will be
randomised in a 1:1 ratio to receive an intravenous bolus of either keratinocyte growth factor (palifermin, 60 μg/kg)
or placebo (0.9% sodium chloride solution) daily for a maximum of 6 days. The primary endpoint of this clinical
study is to evaluate the efficacy of palifermin to improve the oxygenation index at day 7 or the last available
oxygenation index prior to patient discontinuation from the study.
A formal statistical analysis plan has been constructed. Analyses will be carried out on an intention-to-treat basis. A
single analysis is planned at the end of the trial. P = 0.05 will be considered statistically significant and all tests will
be two-sided. For continuously distributed outcomes, differences between groups will be tested using
independent-sample t tests, analysis of variance and analysis of covariance with transformation of variables to
normality or nonparametric equivalents. The trial will be reported in line with the Consolidated Standards of
Reporting Trials (Consort 2010 guidelines).
Trial registration: ISRCTN95690673
Keywords: Keratinocyte growth factor, Palifermin, Acute lung injury, Adult respiratory distress syndrome,
Oxygenation index, Pulmonary oedema, Respiratory failure
Background
Acute lung injury (ALI) is a common clinical syndrome
with a reported incidence of up to 80 per 100,000 patient-
years, characterised by life-threatening respiratory failure
requiring mechanical ventilation and multiple organ fail-
ure, and is a major cause of morbidity and mortality [1-3].
ALI has significant resource implications, prolonging ICU
stay and hospital stay, and requiring rehabilitation in the
community [4-6]. The high incidence, mortality, long-
term consequences and high economic costs mean that
ALI is an extremely important problem.
The pathogenesis of ALI involves pulmonary neutrophil
and macrophage recruitment and injury to the alveolar
epithelium and endothelium, which in part determines the
severity of lung injury [7,8]. The resolution of pulmonary
oedema and improved outcome in ALI is associated with
enhanced alveolar epithelial function, suggesting that a
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strategy to accelerate epithelial repair in ALI may be be-
neficial [9-12]. The Cochrane systematic review of
pharmacological treatments that included 22 studies of 14
different drugs concluded that ‘effective pharmacotherapy
for ALI is extremely limited, with insufficient evidence to
support any specific intervention’ [13]. The recent publi-
cation of two studies from the National Institutes of
Health National Heart, Lung and Blood Institute Acute
Respiratory Distress Syndrome Network of Investigators
investigating nebulised β2-agonist (BALTI Study) and
omega-3 fatty acids with antioxidants (OMEGA study) as
well as the recent publication of the UK-based BALTI-2
trial was disappointing because neither β2-agonists,
omega-3 fatty acids, nor antioxidant supplementation was
effective for ALI [14-16]. The National Heart, Lung and
Blood Institute Working Group considered the future re-
search directions in ALI in 2002 and concluded that cli-
nical trials underpinned by mechanistic investigations
were essential to develop new therapies for ALI [17].
Keratinocyte growth factor (KGF) is a 28 kDa heparin-
binding member of the fibroblast growth factor family
(FGF-7) and specifically binds to the KGF receptor,
expressed primarily in epithelial tissues. KGF acts as a
paracrine mediator of proliferation, differentiation and
upregulation of cytoprotective mechanisms in epithelial
cells, including alveolar type 2 pneumocytes [18]. KGF
modulates several mechanisms recognised to be important
in alveolar epithelial repair and therefore has become of
interest as a potential therapeutic intervention in ALI.
Recombinant human KGF (palifermin) is a 23 N-terminal
amino acid truncated version of KGF [19]. Palifermin (60
μg/kg/day for 6 days) decreases the incidence, duration
and severity of oral mucositis in patients with malignan-
cies associated with chemotherapy and/or radiotherapy
[20]. Such epithelial repair has led to interest in its poten-
tial use to treat epithelial injury in ALI [21]. There is a var-
iety of animal models that have used KGF (between 5 and
10 mg/kg) in the setting of lung injury, in which beneficial
effects were reported [22,23]. Recently, data from a human
ex vivo lung perfusion model of endotoxin-induced lung
injury indicated that treatment with KGF improved lung
endothelial and epithelial barrier function and enhanced
the rate of alveolar fluid clearance, hence reducing alveolar
oedema [24]. The available in vitro, animal and human
model data, as well as clinical studies in mucositis, there-
fore support KGF as a potential therapy for patients with
ALI. We postulate that KGF may improve alveolar epithe-
lial/endothelial barrier dysfunction, and therefore KGF
may improve pulmonary dysfunction in ALI.
Methods/design
Trial summary
KARE is a multicentre, randomised, double-blind,
allocation-concealed, placebo-controlled clinical trial.
Patients fulfilling the American–European Consensus
Conference Definition of ALI [25] will be randomised in
a 1:1 ratio to receive an intravenous bolus of either KGF
(palifermin, 60 μg/kg) or placebo (0.9% sodium chloride
solution) daily for a maximum of 6 days. Randomisation
will be stratified by the presence of severe sepsis requir-
ing vasopressors.
Outcome measures
The primary outcome is to evaluate the efficacy of pali-
fermin to improve the oxygenation index (OI) at day 7 or
the last available OI prior to patient discontinuation from
the study. The OI is a physiological index for the severity
of ALI, and measures both impaired oxygenation and the
amount of mechanical ventilation delivered. We and
others have demonstrated that the OI is independently
predictive of mortality in patients with ALI [26,27]. We
have chosen day 7 as we expect this time interval will
minimise the competing effects of death and extubation,
while allowing a sufficient time interval for biological
benefit effect to occur.
The OI is calculated as follows:
OI ¼ mean airway pressure cmH2Oð Þ  FiO2  100ð Þ=PaO2 kPað Þ
These simple measurements are easily and routinely
collected as part of standard ventilator practice. The sec-
ondary outcomes are the OI at days 3 and 14, physio-
logical indices of pulmonary function, as measured by
respiratory compliance, and the PaO2/FiO2 ratio, at days
3, 7 and 14, as well as a change in the Sequential Organ
Failure Assessment score from baseline to day 7 and 14.
Safety and tolerability will be assessed by the occurrence
of adverse events and suspected unexpected serious
reactions. Although the duration of ventilation and ICU
stay as well as ICU and hospital mortality and 28-day
mortality will also be documented, these clinical outcomes
are not included as major outcome measures because the
study is not powered to assess these outcomes.
The trial design is summarised in Figure 1.
Approvals
The trial was approved by the Office for Research Ethics
Committees Northern Ireland 10/NIR02/32 and the
Medicines and Healthcare Products Regulatory Agency
(MHRA) clinical trial authorisation number 32485/0021/
001-0001 and EudraCT Number 2010-021186-70. The trial
is registered on the International Standard Randomised
Controlled Trial Registry (ISRCTN95690673). The trial is
sponsored by the Belfast Health and Social Care Trust [28].
The trial is being coordinated by the Clinical Research
Support Centre as the clinical trials unit [29]. The trial
has been externally peer reviewed and is funded by the
Northern Ireland Public Health Agency Research and
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Development Division, and will be conducted in accor-
dance with Good Clinical Practice Guidelines, applicable
UK Clinical Trials Regulations and the standard operating
procedures of the sponsor. The trial will be reported in
line with the Consolidated Standards of Reporting Trials
(CONSORT) 2010 guidelines [30].
Inclusion/exclusion criteria
Patients will be eligible to participate in the study if they
fulfil the following inclusion criteria of ALI defined by acute
onset of: hypoxic respiratory failure (PaO2/FiO2 ≤40 kPa);
bilateral infiltrates on chest X-ray consistent with pulmon-
ary oedema; no clinical evidence of left atrial hypertension
or, if measured, pulmonary arterial occlusion pressure ≤18
mmHg; and requirement for positive pressure mechanical
ventilation via an endotracheal tube or tracheostomy. All
four of these ALI criteria must occur within the same 24-
hour period. The onset of ALI is when the last ALI criter-
ion is met. Patients must be enrolled within 72 hours of
ALI onset.
Exclusion criteria included: age <18 years; >72 hours
from the onset of ALI; pregnancy; participation in a clinical
trial of an investigational medicinal product within 30 days;
consent declined; current treatment with KGF; known
hypersensitivity to palifermin or Escherichia coli-derived
proteins; previous adverse reaction to palifermin; history of
active malignancy excluding haematological malignancies;
and chronic liver disease with Child–Pugh score >12.
Trial intervention
Patients will be randomised to palifermin 60 μg/kg or nor-
mal saline placebo daily as a bolus intravenous injection
for up to 6 days in 60 patients with a 1:1 randomisation.
The first dose of study drug will be administered within 4
hours of randomisation and subsequent doses will be at
10:00 am daily, starting on the following calendar day.
Study drug termination criteria
The study drug will be continued until one of the following
conditions is met, whichever comes first: 6 days after ran-
domisation (maximum treatment period); 2 days following
discontinuation of assisted ventilation (unassisted breathing
is defined as extubated with supplemental oxygen or room
air; or open T-tube breathing; or tracheostomy mask
breathing; or CPAP ≤5 cmH2O without pressure support –
patients receiving pressure support via non-invasive ventila-
tion will be defined as receiving assisted ventilation); study
drug-related adverse event; discharge from the critical care
environment; death; discontinuation of active medical treat-
ment; patient or relative request for withdrawal of patient
from the study; and decision by the attending clinician that
the study drug should be discontinued on safety grounds.
Trial procedures
Informed consent procedure
Informed consent will be obtained prior to conducting
any trial-specific procedures.
Within 72 hours
of onset of ALI
Daily screening in ICU
Does the patient have a diagnosis of ALI?
(Acute onset AND PaO2/FiO2 ratio    40kPa AND bilateral infiltrates on CXR 
AND no evidence of left atrial hypertension AND ventilated)
Patients with ALI assessed 
for eligibility
Consent obtained from the 
Per LR or Prof LR
Excluded
Failure to fulfil inclusion and exclusion 
criteria
Excluded
Consent declined
Randomised
to KARE study
N=60
Palifermin
N=30
Placebo
N=30
Data collection
Pulmonary and non-pulmonary organ function
ICU and hospital outcomes
Safety
Blood, BAL and urine samples
Figure 1 Trial schematic diagram.
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As critically ill sedated patients do not have the capacity
to give consent, consistent with requirements of the
EU clinical trial directive, we will obtain written informed
consent/assent from a representative in keeping with
regulatory requirements before randomisation. All surviv-
ing patients will be informed about the trial at the earliest
opportunity after regaining competence and consent to
continue in the trial will be sought. The consent from the
representative will remain valid until a decision on con-
sent to continue is obtained from the patient.
Patient registration and randomisation procedure
After informed consent, the researcher will contact the
clinical trials pharmacist, who will allocate a unique subject
number to the patient and randomise the subject in a 1:1
ratio to the designated treatment group. The clinical trials
pharmacist will dispense the trial drugs. The researcher will
then contact the clinical trials unit and register the
randomised patient.
The total six doses of study drug for each patient will
be dispensed and stored in a secure temperature-
monitored fridge. The study drug will be reconstituted and
administered intravenously by appropriately trained ICU
clinical staff independent of the clinical trial according to
local guidelines, therefore ensuring blinding for the clinical
trial staff. The ICU clinical staff who administer the study
drug will not be involved in any of the study-specific
assessments.
Standardised management
All patients will receive standardised management according
to ICU guidelines with regards to feeding, antibiotic policy,
fluid management and weaning. Patients will be managed
using a standardised ventilation protocol aiming for tidal
volumes of 6ml/kg ideal body weight.
Assessments
A summary of trial procedures is shown in Table 1.
Adverse event management
KARE is recruiting from a patient population who are
already in a life-threatening situation; many of the
participants will therefore be expected to experience ser-
ious adverse events. Events that are expected in this
population and those that are collected as outcomes (for
example, death, organ failure) of the trial will not be
reported as serious adverse events. Other serious adverse
events or suspected unexpected serious reactions that
occur between trial entry and 30 days after the end of
the trial drug administration will be reported by faxing a
serious adverse event log to the sponsor.
End of trial
The trial will end when 60 patients have been recruited
and 28-day follow-up completed.
The trial will be stopped prematurely if: mandated by
the ethics committee; mandated by the MHRA; mandated
by the sponsor (for example, following recommendations
from the Data Monitoring and Ethics Committee); or
funding for the trial ceases. Confirm and accept.
The Office for Research Ethics Committees Northern
Ireland and the MHRA that issued the clinical trial au-
thorisation will be notified in writing if the trial has been
concluded or terminated early.
Sample size and statistical analysis
The primary outcome measure will be the difference in the
OI between the palifermin-treated and placebo-treated
groups at day 7 or the earliest time period prior to day 7
when the OI is available, since some patients will be
Table 1 Trial procedures
Day 1 Days 2 and 3 Day 4 Days 5 and 6 Day 7 Days 8 to 13 Day 14
Eligibility assessment X
Informed consent X
Randomisation X
Baseline data X
Daily data X X X X X X
Study drug administration X X X X
Adverse events X X X X X X X
Bronchoalveolar lavage sampling X X
Blood and urine sampling X X X X
Table 2 Secondary outcomes
Outcome Value in patients with
acute lung injury
Detectable
effect size
Respiratory compliance
(ml/cmH2O)
57.8 (36.5) 27.8
Sequential organ failure
assessment score
7.2 (4.2) 3.2
Data presented as mean (standard deviation).
A statistical analysis plan has been designed and is attached as Additional file 1.
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extubated or will die before day 7. We have chosen day 7
because we expect this time interval will minimise the com-
peting effects of death and extubation, while at the same
time allowing a sufficient time interval for a biological effect
to occur. Based on our data from a recently completed cli-
nical trial in ALI, the mean (standard deviation) OI at day 7
in patients with ALI is 62 (51) cmH2O/kPa [31]. A sample
size of 56 subjects (28 in each group) will have 80% power
at a two-tailed significance level of 0.05 to detect a clinically
significant difference of 39 cmH2O/kPa in OI between
groups. In a previous phase 2 study of similar size, we have
found that an intervention can demonstrate a change in OI
of a similar magnitude [31], confirming a treatment effect
of this size can be achieved.
Although we anticipate few withdrawals or loss to follow-
up, we have allowed for this in the sample size calculation.
In our previous single-centre study of simvastatin in ALI
there were no withdrawals [31]. In a multicentre UK study
of pulmonary artery catheters in ICU patients (PAC-Man),
no patients were lost to follow-up, and only 2.4% withdrew
consent after recovering competency [32]. A dropout rate
of 5% has therefore been estimated and the study will
require a total of 60 patients (30 in each group).
Using the sample size of 60 patients determined from the
primary outcome measure, the differences in the secondary
outcomes at day 7 [31] that can be detected between the
groups are presented in Table 2. All calculations assume
80% power at a two-tailed significance level of 0.05. A
statistical analysis plan has been designed and is attached as
Additional file 1.
Trial status
The trial has been successfully initiated and we are
recruiting patients at the Regional Intensive Care Unit
Royal Victoria Hospital Belfast. There has been one major
amendment to the protocol since design and ethical/
MHRA approval, which has included changing from a
single-site to a multisite study to ensure full recruitment to
the study is achieved, a change from excluding all patients
with an active history of malignancy to allow inclusion of
patients with haematological malignancy, removal of the
exclusion of patients with pancreatitis, extending the re-
cruitment window to 72 hours post onset of ALI as well as
the removal of pulmonary dead space measurement as a
secondary objective.
Additional file
Additional file 1: Statistical analysis plan.
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